Related Experiment Video

Updated: Aug 9, 2026

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

C-reactive protein in atherosclerosis: A causal factor?

Elaine Paffen1, Moniek P M DeMaat

  • 1Hemostasis and Thrombosis Research Centre, Dept. of Hematology, Leiden University Medical Centre, Leiden, The Netherlands.

Cardiovascular Research
|April 21, 2006
PubMed

Insights

C-reactive protein (CRP) is linked to cardiovascular disease and may drive atherosclerosis progression. Further research is needed to clarify CRP's exact role in inflammation and plaque development.

Area of Science:

  • Cardiovascular Science
  • Immunology
  • Biochemistry

Background:

  • Atherosclerosis is a multifactorial inflammatory disease.
  • C-reactive protein (CRP) indicates systemic inflammation and predicts cardiovascular events.
  • CRP presence in atherosclerotic lesions suggests a potential role in plaque progression.

Purpose of the Study:

  • To review recent mechanisms of C-reactive protein (CRP) in atherosclerosis.
  • To discuss the function of CRP in inflammation.
  • To evaluate evidence for CRP's independent role in atherosclerosis development.

Main Methods:

  • Literature review of recent studies on CRP and atherosclerosis.
  • Analysis of CRP's function in inflammatory pathways.
  • Examination of evidence for CRP's direct contribution to atherosclerotic plaque.

Main Results:

  • CRP concentration reflects a patient's inflammatory state.
  • CRP is associated with cardiovascular disease (CVD), myocardial infarction, and stroke.
  • Recent evidence suggests CRP may actively contribute to atherosclerotic plaque progression and instability.

Conclusions:

  • CRP's precise role in atherosclerosis pathogenesis requires further elucidation.
  • Potential mechanisms link CRP to inflammation and atherosclerotic plaque evolution.
  • Contamination in CRP preparations may affect study outcomes.

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...